2022-05-13 16:00Financial Performance - Total revenue for Q1 2022 was RMB 194,785.80 million, a decrease of 50.4% compared to the same period last year[2] - Total revenue for Q1 2022 was 1,947,858 thousand RMB, a decrease of 50.5% compared to 3,928,894 thousand RMB in Q1 2021[20] - Net profit attributable to shareholders was a loss of RMB 286,634.50 million, representing a decline of 965.9% year-over-year[2] - Net loss for Q1 2022 was -2,866,345 thousand RMB, compared to a profit of 331,008 thousand RMB in Q1 2021[22] - The total comprehensive loss for Q1 2022 was -3,063,036 thousand RMB, compared to a gain of 497,630 thousand RMB in Q1 2021[23] Cash Flow and Liquidity - The net cash flow from operating activities was a negative RMB 196,108.60 million, down 347.7% from the previous year[2] - Cash flow from operating activities showed a net outflow of -1,961,086 thousand RMB in Q1 2022, compared to a net inflow of 791,685 thousand RMB in Q1 2021[24] - Cash and cash equivalents at the end of Q1 2022 were 25,544,570 thousand RMB, down from 10,720,968 thousand RMB at the end of Q1 2021[25] - The company reported cash and cash equivalents of 25,153,115 as of March 31, 2022, a decrease from 25,189,667 at the end of 2021[18] Research and Development - R&D investment totaled RMB 251,677.10 million, which is 129.2% of total revenue, an increase of 76.2 percentage points compared to the previous year[3] - Research and development expenses for Q1 2022 were 2,516,771 thousand RMB, an increase of 20.9% from 2,080,683 thousand RMB in Q1 2021[20] Shareholder Information - Basic and diluted earnings per share were both -2.15 RMB, reflecting a significant loss due to decreased collaboration revenue[3][8] - Basic earnings per share for Q1 2022 were -2.15 RMB, compared to 0.28 RMB in Q1 2021[23] - The company reported a total of 1,334,805,269 shares issued, with 91.38% of shares being issued overseas[9] - The largest shareholder, Amgen, holds 246,269,426 shares, representing 18.45% of total shares[12] - Total number of common stock shareholders at the end of the reporting period was 70,047, a slight increase from the previous period[10] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5,094,598.80 million, a decrease of 7.7% from the end of the previous year[3] - Total assets decreased to 50,945,988 from 55,184,711 in the previous year[18] - Total current liabilities decreased to 8,729,555 from 10,204,479 in the previous year[18] - The total liabilities decreased to 13,482,592 thousand RMB in Q1 2022 from 15,258,939 thousand RMB in Q1 2021[19] - The company has a total of 1,279,775 in long-term borrowings as of March 31, 2022, compared to 1,289,780 at the end of 2021[18] Operational Costs - Total operating costs increased to 4,720,140 thousand RMB in Q1 2022, up 33% from 3,547,421 thousand RMB in Q1 2021[20] - The company reported a significant increase in sales expenses, which rose to 1,317,988 thousand RMB in Q1 2022 from 782,050 thousand RMB in Q1 2021, reflecting a 68.3% increase[20] Industry Risks and Focus - The company emphasizes the high risks and long development cycles associated with the biopharmaceutical industry, which may impact future performance[15] - The company is focused on maintaining its intellectual property rights and navigating regulatory approvals for its drug candidates[15]